Replimune (REPL) Net Income (2017 - 2026)
Replimune (REPL) posted Net Income of -$73.2 million for Q1 2026, down 3.14% sequentially from -$70.9 million in Q4 2025, and up 1.34% YoY from -$72.2 million in Q1 2025.
Replimune (REPL) Net Income (2017 - 2026) Analysis & Trends
Replimune has reported Net Income for 10 years, with the latest figure at -$73.2 million in Q1 2026.
- Quarterly Net Income rose 1.34% year-over-year to -$73.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$395.8 million (down 60.01% YoY) and the FY2026 annual result came in at -$313.9 million, down 26.91% from the prior year.
- Net Income slipped to -$73.2 million in Q1 2026 per REPL's latest filing, from -$70.9 million in the prior quarter.
- Over five years, Net Income peaked at -$31.6 million in Q1 2022 and troughed at -$128.7 million in Q2 2025.
- A 5-year average of -$62.6 million and a median of -$53.8 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income surged 51.52% in 2022, then plunged 139.39% in 2025.
- Over 5 years, Net Income stood at -$39.7 million in 2022, then fell by 28.8% to -$51.1 million in 2023, then declined by 29.77% to -$66.3 million in 2024, then declined by 6.94% to -$70.9 million in 2025, then retreated by 3.14% to -$73.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$73.2 million, -$70.9 million, and -$122.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | -73.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.17 Mn |
| Dec 31, 2025 | -70.94 Mn |
| Sep 30, 2025 | -122.92 Mn |
| Jun 30, 2025 | -128.72 Mn |
| Mar 31, 2025 | -74.16 Mn |
| Dec 31, 2024 | -66.34 Mn |
| Sep 30, 2024 | -53.06 Mn |
| Jun 30, 2024 | -53.77 Mn |
| Mar 31, 2024 | -55.08 Mn |
| Dec 31, 2023 | -51.12 Mn |
| Sep 30, 2023 | -60.04 Mn |
| Jun 30, 2023 | -49.56 Mn |
| Mar 31, 2023 | -49.25 Mn |
| Dec 31, 2022 | -39.69 Mn |
| Sep 30, 2022 | -43.10 Mn |
| Jun 30, 2022 | -42.25 Mn |
| Mar 31, 2022 | -31.62 Mn |
| Dec 31, 2021 | -81.86 Mn |
| Sep 30, 2021 | -82.05 Mn |
| Jun 30, 2021 | -80.79 Mn |